This biopharma superlative is a no-brainer: The most noteworthy drug approval of the year goes, hands-down, to the two CAR-T drugs that hit the market earlier this year.
Kymriah, from Novartis (NVS), was approved in late August, with a price tag set at $475,000. And Yescarta, developed by Kite Pharma and acquired by Gilead Sciences (GILD), was approved in October, with a $373,000 set price. Both work with just a single infusion.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- Online intelligence briefings
- Frequent opportunities to engage with veteran beat reporters and industry experts
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
About the Author Reprints
pls. deliver me news about brain cancer treatment.